Monjuvi, combined with Rituxan and Revlimid, extends progression-free survival to 22 months, reducing disease progression risk by over 50%. The inMIND trial's design and diverse patient population ...
Maintenance therapy with Ninlaro and Revlimid in patients with recently diagnosed multiple myeloma who underwent a stem cell transplant may safely improve survival, although more research is needed ...
BOSTON, Dec 1 (Reuters) - Sales of Celgene Corp's cancer drug Revlimid could rise by more than a third if data due to be presented next Monday at the annual meeting of the American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results